ECSP12012230A - Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores - Google Patents

Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores

Info

Publication number
ECSP12012230A
ECSP12012230A ECSP12012230A ECSP12012230A EC SP12012230 A ECSP12012230 A EC SP12012230A EC SP12012230 A ECSP12012230 A EC SP12012230A EC SP12012230 A ECSP12012230 A EC SP12012230A
Authority
EC
Ecuador
Prior art keywords
robo1
fusion protein
tumor treatment
compounds
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Jean-Pascal Herault
Pierre Fons
Béatrice Cameron
Tarik Dabdoubi
Francis Blanche
Frédérique Dol-Gleizes
Catherine Prades
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012230(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP12012230A publication Critical patent/ECSP12012230A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a compuestos definidos por la fórmula (I) en la que las variables R1-R8 se definen como en la descripción, poseen actividad farmacológica valiosa. Particularmente, los compuestos son inhibidores de la proteína de transferencia de éster de colesterol (CETP) y, por lo tanto, son adecuados para el tratamiento y prevención de enfermedades que pueden influenciarse por la inhibición de esta enzima.
ECSP12012230 2010-04-14 2012-10-08 Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores ECSP12012230A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (1)

Publication Number Publication Date
ECSP12012230A true ECSP12012230A (es) 2012-11-30

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012230 ECSP12012230A (es) 2010-04-14 2012-10-08 Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores

Country Status (27)

Country Link
US (1) US9493529B2 (es)
EP (1) EP2558489A1 (es)
JP (1) JP5858442B2 (es)
KR (1) KR20130059329A (es)
CN (1) CN102884076A (es)
AR (1) AR080891A1 (es)
AU (1) AU2011239839B2 (es)
BR (1) BR112012026020A2 (es)
CA (1) CA2796303A1 (es)
CL (1) CL2012002879A1 (es)
CR (1) CR20120508A (es)
DO (1) DOP2012000265A (es)
EA (1) EA201291044A1 (es)
EC (1) ECSP12012230A (es)
FR (1) FR2958936A1 (es)
GT (1) GT201200275A (es)
IL (1) IL222382A (es)
MA (1) MA34221B1 (es)
MX (1) MX338981B (es)
NI (1) NI201200155A (es)
PE (1) PE20130199A1 (es)
PH (1) PH12012502044A1 (es)
SG (1) SG184529A1 (es)
TN (1) TN2012000473A1 (es)
TW (1) TW201142024A (es)
UY (1) UY33334A (es)
WO (1) WO2011128561A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE175248T1 (de) 1993-04-05 1999-01-15 Daikin Ind Ltd Polytetrafluorethylenfaser, baumwollartiges, diese faser enthaltendes material, und verfahren zu deren herstellung
PH12013501205A1 (en) * 2010-12-23 2013-07-29 Sanofi Sa Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
CN104271197A (zh) 2012-01-05 2015-01-07 波士顿医疗中心有限公司 用于诊断和治疗肾脏疾病的slit-robo信号
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
MX2019014480A (es) * 2017-06-02 2020-01-23 Pfizer Proteinas recombinantes robo2, composiciones, metodos y usos de las mismas.
EP3672992A4 (en) 2017-08-24 2021-05-19 Bar-Ilan University ROUNDABOUT (ROBO) RECEPTOR INHIBITORS AND USES THEREOF
EP3932430A4 (en) * 2019-02-27 2023-02-01 Daewoong Pharmaceutical Co., Ltd. ALBUMIN-RELATED COMPOSITION COMPRISING LRRD2 OF THE SLIT3 PROTEIN FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
CA3136663A1 (en) 2019-04-23 2020-10-29 The Regents Of The University Of California Compositions and methods useful in promoting milk production
TW202511284A (zh) * 2023-09-14 2025-03-16 大陸商北京拓界生物醫藥科技有限公司 包含robo結構域的蛋白及其醫藥用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
EP1025231B1 (en) * 1997-10-20 2003-07-16 The Regents of the University of California Robo: a family of polypeptides and nucleic acids involved in nerve cell guidance
AU752168B2 (en) * 1998-04-02 2002-09-05 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
DK1572169T3 (da) 2002-03-08 2013-10-21 Shanghai Inst Biol Sciences Påvisning og modulering af Slit- og Robo-medieret angiogenese og anvendelser deraf
JP4643450B2 (ja) * 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
CA2553187A1 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility
MX2008012896A (es) * 2006-04-05 2008-10-14 Abbott Biotech Ltd Purificacion de anticuerpos.
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
WO2008134046A1 (en) * 2007-04-27 2008-11-06 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
ES2672769T3 (es) 2007-08-29 2018-06-18 Sanofi Anticuerpos anti-CXCR5 humanizados, derivados de los mismos y sus usos
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof

Also Published As

Publication number Publication date
CL2012002879A1 (es) 2013-03-22
IL222382A (en) 2016-06-30
MX2012011822A (es) 2012-11-12
EA201291044A1 (ru) 2013-04-30
PH12012502044A1 (en) 2017-07-26
KR20130059329A (ko) 2013-06-05
SG184529A1 (en) 2012-11-29
EP2558489A1 (fr) 2013-02-20
MA34221B1 (fr) 2013-05-02
UY33334A (es) 2011-12-01
IL222382A0 (en) 2012-12-31
CA2796303A1 (fr) 2011-10-20
PE20130199A1 (es) 2013-03-09
US20130039912A1 (en) 2013-02-14
WO2011128561A1 (fr) 2011-10-20
DOP2012000265A (es) 2013-02-28
MX338981B (es) 2016-05-06
TW201142024A (en) 2011-12-01
JP2013523172A (ja) 2013-06-17
GT201200275A (es) 2014-01-24
US9493529B2 (en) 2016-11-15
BR112012026020A2 (pt) 2016-06-28
NI201200155A (es) 2013-02-05
CR20120508A (es) 2012-11-01
JP5858442B2 (ja) 2016-02-10
AU2011239839A1 (en) 2012-11-08
TN2012000473A1 (fr) 2014-01-30
AR080891A1 (es) 2012-05-16
FR2958936A1 (fr) 2011-10-21
CN102884076A (zh) 2013-01-16
AU2011239839B2 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
ECSP12012230A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
CR20150217A (es) Inhibidores de histona demetilasas
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
CR20110686A (es) Pirimidinonas como ihnibidores de pi3k
CR20140111A (es) Heterociclilaminas como inhibidores de pi3k
MX2019003738A (es) Compuestos antivirales.
CO7240375A2 (es) Compuestos tricíclicos sustituidos como inhibidores del fgfr
UY33969A (es) Inhibidores tricíclicos fusionados dobles de las cdk 4/6 y de la flt3
CR20120659A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
PY1212975A (es) Compuestos de azabiclo o quinuclidin-carbamato como inhibidores de glucosilceramida sintasa
UY33001A (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
NI201400078A (es) Derivados de lactamas útiles como inhibidores mutantes de idh1
GT201400133A (es) Inhibidores de bromodominios
BR112012024117A2 (pt) inibidores de pirrolopirazina quinase
MX2019010602A (es) Inhibidores de cdk.
EA201290988A1 (ru) Стереоселективный синтез фосфорсодержащих активных соединений
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
UY33766A (es) COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2
UY33272A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad